Art

J-GLOBAL ID：201802280295845158   Reference number：18A2011047

Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma

転移性腎細胞癌を有する日本人患者におけるスニチニブ血漿中濃度および臨床転帰の間の関係性

Author (14)： TAKASAKI Shinya (Tohoku Univ. Hospital, Miyagi, JPN) ,  KAWASAKI Yoshihide (Tohoku Univ. Graduate School of Medicine, Miyagi, JPN) ,  KIKUCHI Masafumi (Tohoku Univ. Hospital, Miyagi, JPN) ,  TANAKA Masaki (Tohoku Univ. Hospital, Miyagi, JPN) ,  SUZUKA Masato (Tohoku Univ. Hospital, Miyagi, JPN) ,  NODA Aoi (Tohoku Univ. Hospital, Miyagi, JPN) ,  SATO Yuji (Tohoku Univ. Hospital, Miyagi, JPN) ,  YAMASHITA Shinichi (Tohoku Univ. Graduate School of Medicine, Miyagi, JPN) ,  MITSUZUKA Koji (Tohoku Univ. Graduate School of Medicine, Miyagi, JPN) ,  SAITO Hideo (Sendai Medical Center, Miyagi, JPN) ,  ITO Akihiro (Tohoku Univ. Graduate School of Medicine, Miyagi, JPN) ,  YAMAGUCHI Hiroaki (Tohoku Univ. Hospital, Miyagi, JPN) ,  ARAI Yoichi (Tohoku Univ. Graduate School of Medicine, Miyagi, JPN) ,  MANO Nariyasu (Tohoku Univ. Hospital, Miyagi, JPN)
Material： International Journal of Clinical Oncology  (Int J Clin Oncol)
Volume： 23  Issue： 5  Page： 936-943  Publication year： Oct. 2018 
JST Material Number： L3966A  ISSN： 1341-9625  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： Interrupted treatment ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A2011047&from=J-GLOBAL&jstjournalNo=L3966A") }}

JST classification (3)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Urogenital tumors(=neoplasms)  (GM04000S) ,  Clinical biopharmacy  (GY01022L)

Substance index (1)： Sunitinib

Reference (24)：

• Yoshimura K, Uemura H (2016) Pharmacotherapies for renal cell carcinoma in Japan. Int J Urol 23:194-202
• Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337
• Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
• Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35
• Gao B, Yeap S, Clements A et al (2012) Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 30:4017-4025

Terms in the title (7)： 転移性腎細胞癌 ,  日本人 ,  患者 ,  スニチニブ ,  血漿中濃度 ,  臨床転帰 ,  関係性